ANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings Guidance

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued an update on its FY17 earnings guidance on Thursday morning. The company provided EPS guidance of $3.83-4.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.84. The company issued revenue guidance of $182.10 million, compared to the consensus revenue estimate of prior $3.58-3.94.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ ANIP) opened at $61.97 on Friday. The firm has a market capitalization of $693.99 million, a PE ratio of 17.78 and a beta of 2.85. The company has a quick ratio of 2.49, a current ratio of 3.45 and a debt-to-equity ratio of 0.83.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. ANI Pharmaceuticals’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.09 EPS. equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.52 earnings per share for the current year.

A number of equities analysts have commented on the stock. BidaskClub downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research report on Saturday, August 5th. Canaccord Genuity restated a buy rating and set a $66.00 price objective (up previously from $60.00) on shares of ANI Pharmaceuticals in a research report on Monday, October 16th. Finally, ValuEngine upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $67.33.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

What are top analysts saying about ANI Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ANI Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit